Media stories about Sagent Pharmaceuticals (NASDAQ:SGNT) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sagent Pharmaceuticals earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.7878952062519 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

TRADEMARK VIOLATION NOTICE: “Sagent Pharmaceuticals (NASDAQ:SGNT) Receiving Somewhat Favorable Media Coverage, Report Shows” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/sagent-pharmaceuticals-nasdaqsgnt-receiving-somewhat-favorable-media-coverage-report-shows/1470571.html.

Sagent Pharmaceuticals Company Profile

Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.

Receive News & Ratings for Sagent Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.